Merck Drops COVID-19 Vaccine Studies After Phase 1 Data Churn Out Inferior Efficacy ResultsBenzinga • 01/25/21
Merck to discontinue development of COVID-19 vaccines, focus on two investigational therapiesMarket Watch • 01/25/21
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic CandidatesBusiness Wire • 01/25/21
Week 4 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 01/24/21
Cocrystal Pharma (COCP) Completes Research Obligations With MerckZacks Investment Research • 01/20/21
Merck KGaA, Darmstadt, Germany Announces Update on the INTR@PID Clinical Program Including Lung 037 StudyPRNewsWire • 01/20/21
Merck Just Sold Its Equity Stake In Moderna — But Is Merck Stock A Buy?Investors Business Daily • 01/20/21
U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and OlderBusiness Wire • 01/12/21
Merck & Co., Inc. (MRK) CEO Ken Frazier Presents at 39th Annual JPMorgan Healthcare Conference (Transcript)Seeking Alpha • 01/12/21
Merck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4Business Wire • 01/08/21